Rational design, synthesis and biological evaluation of novel 2-(substituted amino)-[1,2,4]triazolo[1,5-a]pyrimidines as novel tubulin polymerization inhibitors. 2022

Lin Chen, and Tang-Yang Ji, and Xian-Sen Huo, and Zhi-Yu Zeng, and Wei-Xuan Ye, and Chen-Chen Dai, and Yu-Qi Zhang, and Wen-Wei You, and Pei-Liang Zhao
Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou, 510515, PR China.

Following our previously reported compound 3, we designed and synthesized a series of new 2-(substituted amino)- [1,2,4]triazolo[1,5-a]pyrimidines as potential tubulin polymerization inhibitors. Among them, analogue 4k, having a 3-hydroxy-4-methoxyphenylamino group, was observed to display excellent antiproliferative activity toward HeLa, HCT116, A549, and T47D with the IC50 values of 0.31, 1.28, 3.99 and 10.32 μM, respectively, which were approximately 32, 48, 4, and 5-fold improvement compared with 3. Importantly, 4k possessed significant selectivity in inhibiting cancer cell lines over the normal HEK293 cells. Moreover, futher mechanism analysis demonstrated that 4k caused G2/M arrest, induced cells apoptosis in HeLa cells, and manifested significant tubulin polymerization inhibitory activity with the IC50 value of 4.9 μM, which is comparable to CA-4 (IC50 = 4.2 μM). The observations performed in this study reveal that 2-arylamino- [1,2,4]triazolo[1,5-a]pyrimidines represent a novel class of tubulin polymerization inhibitors with potent antiproliferative efficacy.

UI MeSH Term Description Entries
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014404 Tubulin A microtubule subunit protein found in large quantities in mammalian brain. It has also been isolated from SPERM FLAGELLUM; CILIA; and other sources. Structurally, the protein is a dimer with a molecular weight of approximately 120,000 and a sedimentation coefficient of 5.8S. It binds to COLCHICINE; VINCRISTINE; and VINBLASTINE. alpha-Tubulin,beta-Tubulin,delta-Tubulin,epsilon-Tubulin,gamma-Tubulin,alpha Tubulin,beta Tubulin,delta Tubulin,epsilon Tubulin,gamma Tubulin
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis

Related Publications

Lin Chen, and Tang-Yang Ji, and Xian-Sen Huo, and Zhi-Yu Zeng, and Wei-Xuan Ye, and Chen-Chen Dai, and Yu-Qi Zhang, and Wen-Wei You, and Pei-Liang Zhao
April 2022, Bioorganic chemistry,
Lin Chen, and Tang-Yang Ji, and Xian-Sen Huo, and Zhi-Yu Zeng, and Wei-Xuan Ye, and Chen-Chen Dai, and Yu-Qi Zhang, and Wen-Wei You, and Pei-Liang Zhao
August 2021, European journal of medicinal chemistry,
Lin Chen, and Tang-Yang Ji, and Xian-Sen Huo, and Zhi-Yu Zeng, and Wei-Xuan Ye, and Chen-Chen Dai, and Yu-Qi Zhang, and Wen-Wei You, and Pei-Liang Zhao
May 2012, Steroids,
Lin Chen, and Tang-Yang Ji, and Xian-Sen Huo, and Zhi-Yu Zeng, and Wei-Xuan Ye, and Chen-Chen Dai, and Yu-Qi Zhang, and Wen-Wei You, and Pei-Liang Zhao
January 2017, European journal of medicinal chemistry,
Lin Chen, and Tang-Yang Ji, and Xian-Sen Huo, and Zhi-Yu Zeng, and Wei-Xuan Ye, and Chen-Chen Dai, and Yu-Qi Zhang, and Wen-Wei You, and Pei-Liang Zhao
May 2011, Journal of medicinal chemistry,
Lin Chen, and Tang-Yang Ji, and Xian-Sen Huo, and Zhi-Yu Zeng, and Wei-Xuan Ye, and Chen-Chen Dai, and Yu-Qi Zhang, and Wen-Wei You, and Pei-Liang Zhao
October 2021, Bioorganic chemistry,
Lin Chen, and Tang-Yang Ji, and Xian-Sen Huo, and Zhi-Yu Zeng, and Wei-Xuan Ye, and Chen-Chen Dai, and Yu-Qi Zhang, and Wen-Wei You, and Pei-Liang Zhao
September 2013, Bioorganic & medicinal chemistry letters,
Lin Chen, and Tang-Yang Ji, and Xian-Sen Huo, and Zhi-Yu Zeng, and Wei-Xuan Ye, and Chen-Chen Dai, and Yu-Qi Zhang, and Wen-Wei You, and Pei-Liang Zhao
March 2019, European journal of medicinal chemistry,
Lin Chen, and Tang-Yang Ji, and Xian-Sen Huo, and Zhi-Yu Zeng, and Wei-Xuan Ye, and Chen-Chen Dai, and Yu-Qi Zhang, and Wen-Wei You, and Pei-Liang Zhao
November 2021, European journal of medicinal chemistry,
Lin Chen, and Tang-Yang Ji, and Xian-Sen Huo, and Zhi-Yu Zeng, and Wei-Xuan Ye, and Chen-Chen Dai, and Yu-Qi Zhang, and Wen-Wei You, and Pei-Liang Zhao
January 2012, Iranian journal of pharmaceutical research : IJPR,
Copied contents to your clipboard!